Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …

Simple Summary Despite significant advances in the treatment of cancer, it remains a major
cause of death worldwide and new treatment options are constantly being sought. An …

PURPOSE Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for
advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch …

Gastrointestinal stromal sarcomas (GISTs) are the most common mesenchymal tumours
originating in the digestive tract. They have a characteristic morphology, are generally …

Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of
mesenchymal origin. GIST spans a wide clinical spectrum that ranges from tumors with …

Background: Sodium–glucose cotransporter-2 (SGLT2) inhibitors have been shown to
decrease the adverse cardiac events and risks of cardiovascular mortality among patients …

Sarcoma subtype classification is currently mainly based upon histopathological
morphology. Molecular analyses have emerged as an efficient addition to the diagnostic …

As a multitargeted kinase inhibitor, sunitinib has carved its way into demonstrating itself as a
most effective tyrosine kinase inhibitor in the treatment of metastatic renal cell carcinoma …

Simple Summary Gastrointestinal stromal tumors (GISTs) are the most common
mesenchymal tumors of the gastrointestinal tract, mostly driven by activating mutations in KIT …

Cancer and cardiovascular disorders are known as the two main leading causes of mortality
worldwide. Cardiotoxicity is a critical and common adverse effect of cancer-related …